Eli Lilly and Company‘s Phase 3 ATTAIN-1 clinical trial for orforglipron, an experimental oral GLP-1 receptor agonist for weight control, has shown encouraging results. The once-daily medication led to significant weight loss and improvements in a number of cardiometabolic risk markers, according to a study presented at the 2025 Annual Meeting of the European Association for the Study of Diabetes (EASD) and published in The New England Journal of Medicine.
The effectiveness and safety of orforglipron in people who are obese or overweight and have a weight-related medical problem but do not have diabetes were assessed in the ATTAIN-1 trial. Participants who received the highest dosage of the medication lost an average of 27.3 pounds (12.4% of body weight) at 72 weeks, which was a significant result. The primary goal of better body weight loss in comparison to a placebo was achieved by all three orforglipron dosages (6 mg, 12 mg, and 36 mg).
All doses resulted in clinically significant decreases in waist circumference and body weight (≥10%, ≥15%, and ≥20%), and the trial also met important secondary objectives. Orforglipron may be a major new therapy option for the millions of people who suffer from obesity, according to these studies.
Read More: Eli Lilly Reports Strong Q2 2025 Financial Results with 38% Revenue Growth
In the ATTAIN-1 trial, orforglipron’s safety profile aligned with that of the well-established GLP-1 receptor agonist class of drugs. The majority of side effects were mild to moderate in severity and were associated with the gastrointestinal tract. These included vomiting, diarrhea, constipation, and nausea. Adverse event-related treatment discontinuation rates were marginally greater in the orforglipron groups than in the placebo group. Crucially, there was no hepatic safety signal detected.
GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer
GSK’s risvutatug rezetecan has officially secured Orphan Drug Designation from Japan’s MHLW for the treatment of small-cell lung cancer (SCLC). Supported by durable response data […]
Eli Lilly is proceeding with global regulatory submissions for orforglipron for the treatment of obesity in light of these encouraging results; the first regulatory action is expected as early as next year. In 2026, a type 2 diabetes treatment submission is anticipated.
Last Modified:
Graduated from the University of Kerala with B.Sc. Botany and Biotechnology. Attained Post-Graduation in Biotechnology from the Kerala University of Fisheries and Ocean Science (KUFOS) with the third rank. Conducted various seminars and attended major Science conferences. Done 6 months of internship in ICMR – National Institute of Nutrition, Hyderabad. 5 years of tutoring experience.
